Oncologix Tech Stock Cash Per Share
OCLG Stock | USD 0.0001 0.00 0.00% |
Oncologix Tech fundamentals help investors to digest information that contributes to Oncologix Tech's financial success or failures. It also enables traders to predict the movement of Oncologix Pink Sheet. The fundamental analysis module provides a way to measure Oncologix Tech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Oncologix Tech pink sheet.
Oncologix |
Oncologix Tech Company Cash Per Share Analysis
Oncologix Tech's Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.
Competition |
In accordance with the recently published financial statements, Oncologix Tech has a Cash Per Share of 0.0 times. This is 100.0% lower than that of the Health Care Providers & Services sector and about the same as Health Care (which currently averages 0.0) industry. The cash per share for all United States stocks is 100.0% higher than that of the company.
Did you try this?
Run Bond Analysis Now
Bond AnalysisEvaluate and analyze corporate bonds as a potential investment for your portfolios. |
All Next | Launch Module |
Oncologix Fundamentals
Return On Asset | -0.12 | |||
Profit Margin | (0.38) % | |||
Operating Margin | (0.13) % | |||
Current Valuation | 3.18 M | |||
Shares Outstanding | 340.13 M | |||
Price To Earning | (0.03) X | |||
Price To Sales | 0.17 X | |||
Revenue | 2.85 M | |||
Gross Profit | 614.41 K | |||
EBITDA | (572.25 K) | |||
Net Income | (2.37 M) | |||
Cash And Equivalents | 86.31 K | |||
Total Debt | 3.97 M | |||
Current Ratio | 0.28 X | |||
Book Value Per Share | (0) X | |||
Cash Flow From Operations | (24.2 K) | |||
Earnings Per Share | (0.01) X | |||
Number Of Employees | 191 | |||
Beta | 1.27 | |||
Market Capitalization | 612.23 K | |||
Total Asset | 1.5 M | |||
Retained Earnings | (49.86 M) | |||
Working Capital | (3.35 M) | |||
Current Asset | 1.31 M | |||
Current Liabilities | 4.67 M | |||
Z Score | -47.6 | |||
Net Asset | 1.5 M |
About Oncologix Tech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Oncologix Tech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Oncologix Tech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Oncologix Tech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Oncologix Pink Sheet
Oncologix Tech financial ratios help investors to determine whether Oncologix Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Oncologix with respect to the benefits of owning Oncologix Tech security.